CRC accounted for 58% of path_MLH1 associated cancers (n = 36), 46% of path_MSH2 (n = 26), 40% path_MSH6 (n = 4) and 50% of path_PMS2 mutation associated cancers (n = 5). Here, MSH6 is linked to cancer.